Drugs / TORAPSEL
TORAPSEL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00876902 | May 2008 → Mar 2009 | ischemic disease | Y's Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00450398 | Mar → Dec 2007 | liver disorder | Y's Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TORAPSEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108056 ↗ |
| Known as | rPSGL-Ig | “The selectin antagonist known as recombinant P-selectin glycoprotein ligand IgG (rPSGL-Ig) blocks leukocyte adhesion and protects against transplantation ischemia reperfusion...” PMID 21401865 ↗ Mar 2011 |
| Known as | WAY 164339 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108056 ↗ |
| Known as | YSPSL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00450398 ↗ |
| Action | Inhibit | “The selectin antagonist known as recombinant P-selectin glycoprotein ligand IgG (rPSGL-Ig) blocks leukocyte adhesion” PMID 21401865 ↗ Mar 2011 |
| Modality | Protein / enzyme biologic | “recombinant P-selectin glycoprotein ligand-Ig” NCT00450398 ↗ |
| Route | Other | “into the portal vein prior to transplant” NCT00450398 ↗ |